Page last updated: 2024-12-07

prolinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Prolinamide is a cyclic amino acid derivative. It is a white solid that is soluble in water. Prolinamide has been studied for its potential biological activity, particularly its effects on protein folding and aggregation. It has been found to inhibit the aggregation of amyloid-beta peptides, which are implicated in Alzheimer's disease. Prolinamide has also been investigated for its potential as a therapeutic agent for other neurodegenerative diseases, such as Parkinson's disease and Huntington's disease. The cyclic structure of prolinamide makes it a good scaffold for the development of novel drugs. For example, prolinamide derivatives have been synthesized and evaluated for their ability to inhibit the activity of enzymes involved in cancer cell growth. Prolinamide is also a building block for the synthesis of more complex molecules, such as peptides and proteins. The study of prolinamide and its derivatives is important for understanding the biological and medicinal properties of these compounds.'

prolinamide: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

L-prolinamide : The carboxamide derivative of L-proline. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID111306
CHEMBL ID1222059
CHEBI ID21374
SCHEMBL ID240170
MeSH IDM0157937
PubMed CID550774
CHEMBL ID1599880
SCHEMBL ID221055
MeSH IDM0157937

Synonyms (108)

Synonym
prolinamide
CHEMBL1222059
(s)-prolinamide
NCGC00159402-02
l-prolinamide, 98%
l-proline amide
l-prolinamide
CHEBI:21374 ,
(s)-pyrrolidine-2-carboxamide
7531-52-4
(s)-2-pyrrolidinecarboxamide
P1382
(2s)-pyrrolidine-2-carboxamide
A839595
58274-20-7
(2s)-2-pyrrolidinecarboxamide
h-pro-nh2
C19781
LPD ,
(2s)pyrrolidine-2-carboxamide
AKOS005174571
(2s)-2-carbamoylpyrrolidine
unii-vd6pqk9dhg
vd6pqk9dhg ,
einecs 231-397-0
ec 231-397-0
BP-10428
AM20100732
AKOS015854494
c5h10n2o
SCHEMBL240170
s)-pyrrolidine-2-carboxylic acid amide
prolinamide, l-
2-pyrrolidinecarboxamide, (2s)-
proline amide
(s)-proline amide
mfcd00005253
DTXSID00226268
proline imide
l-pronh2
(2s)-prolinamide
(s)-2-pyrrolidine carboxamide
l-proline amid
pronh2
h-l-pro-nh2
(s)-pyrrolidine-2-carboxylic acid amide
h-pronh2
l-(-)-prolinamide
l-(-) prolinamide
l-prolineamide
2-pyrrolidinecarboxamide #
2-pyrrolidinecarboxamide, (s)-
Q-102892
TS-01579
AC-24602
AC-25877
J-524162
F1905-7145
CS-D1209
Q27103084
(s)-prrolidine-2-carboxamide
A26952
(s)-pyrrolidine-2-carboxylic acid amide;(s)-prolinamide; l-proline amide;l-(-)-prolinamide
(2s)-pyrrolidine-2-carboxamide (l-prolinamide)
HY-20582
EN300-114103
HMS1756P16
MLS001006873
smr000384370
AKOS000199879
pyrrolidine-2-carboxylic acid amide
pyrrolidine-2-carboxamide
FT-0652250
STK623492
2-pyrrolidinecarboxamide
A831815
HMS2679O08
M02953
h-dl-pro-nh2
EN300-07127
2812-47-7
BBL010815
FT-0628003
FT-0630082
FT-0613401
AM20080102
AB04106
AB00394
SCHEMBL221055
AKOS016051298
SY003793
pyrrolidine-2-carboxylic acid amid
VLJNHYLEOZPXFW-UHFFFAOYSA-N
CHEMBL1599880
dl-prolinamide
h-dl-pro-nh2, aldrichcpr
mfcd03788250
dl-pro-nh2
h-dl-pro-nh hcl
BS-12794
SY008764
Z56945990
BCP07471
F16286
pyrrolidine-2-carboximidic acid
DTXSID20973828
CS-0450473
SY032133

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Combining molecular modeling and PH4 in silico screening of the VL resulted in the proposed novel potent antituberculotic agent candidates with favorable pharmacokinetic profiles."( Computer-Aided Design of Orally Bioavailable Pyrrolidine Carboxamide Inhibitors of Enoyl-Acyl Carrier Protein Reductase of Mycobacterium tuberculosis with Favorable Pharmacokinetic Profiles.
Esmel, A; Frecer, V; Keita, M; Kone, M; Kouassi, AF; Megnassan, E; Miertus, S; N'Guessan, YT, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
"6 million drug like orally bioavailable analogues and PH4 in silico screened to identify new potent PCAMs with predicted IC50(pre) reaching up to 5 nM."( Computer-Aided Design of Orally Bioavailable Pyrrolidine Carboxamide Inhibitors of Enoyl-Acyl Carrier Protein Reductase of Mycobacterium tuberculosis with Favorable Pharmacokinetic Profiles.
Esmel, A; Frecer, V; Keita, M; Kone, M; Kouassi, AF; Megnassan, E; Miertus, S; N'Guessan, YT, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
amino acid amideAn amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group.
pyrrolidinecarboxamide
L-proline derivativeA proteinogenic amino acid derivative resulting from reaction of L-proline at the amino group or the carboxy group, or from the replacement of any hydrogen of L-proline by a heteroatom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA polymerase betaHomo sapiens (human)Potency100.00000.022421.010289.1251AID485314
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID500816Inhibition of nitrogen-starved wild type sigma1278b yeast Gap1-mediated amino acid uptake at 5 mM after 60 secs relative to L-citrulline2009Nature chemical biology, Jan, Volume: 5, Issue:1
Transport and signaling via the amino acid binding site of the yeast Gap1 amino acid transceptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.08)18.7374
1990's0 (0.00)18.2507
2000's16 (33.33)29.6817
2010's25 (52.08)24.3611
2020's6 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.25 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index100.86 (26.88)
Search Engine Supply Index3.80 (0.95)

This Compound (38.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other41 (100.00%)84.16%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]